In a groundbreaking advancement for neurodegenerative disease diagnostics, Roche and Eli Lilly have received US Food and Drug Administration (FDA) approval for their blood-based test to detect Alzheimer’s disease, marking a major leap toward earlier, simpler, and more accessible diagnosis of the condition. The newly approved
Hema Krishna P, Consultant - Neurology and Movement Disorders, Aster CMI Hospital, Bangalore Guillain-Barré Syndrome (GBS) is a rare but serious autoimmune neurological disorder in which the body’s immune system attacks the peripheral nervous system. This system, consisting of nerves outside the brain and spinal cord,
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
